ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SQD Merrill Lynch

14.48
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Merrill Lynch NYSE:SQD NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 14.48 0.00 01:00:00

EDISON EQUITY RESEARCH: SQI DIAGNOSTICS

29/09/2015 4:12pm

InvestorsHub NewsWire


EDISON EQUITY RESEARCH:SQI DIAGNOSTICS - TAPPING INTO CONSIDERABLE MARKET OPPORTUNITIES

SQI has made steady progress over recent months in signing new agreements with drug development companies in its high-volume assay business. Encouragingly, service revenues are now booked for custom-made tests early on in development, albeit at modest levels. While the conversion of customers from early contract work/validation to meaningful revenue-generating accounts is slower than expected, industry interest continues to grow steadily for SQI’s multiplexing technology capabilities, as does its pipeline of potential customers.

SQI Diagnostics is a Canadian diagnostics company. It develops and sells multiplexed research diagnostics to pharmaceutical companies to support clinical research and in vitro diagnostics tests to centralised diagnostics labs for diagnosing autoimmune diseases.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports

1 Year Merrill Lynch Chart

1 Year Merrill Lynch Chart

1 Month Merrill Lynch Chart

1 Month Merrill Lynch Chart